| Jin, Hui M |
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects |
|
|
| Not yet recruiting | 3 | 408 | RoW | TQF3510 (Semaglutide Injection), Wegovy® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Obesity | 07/26 | 08/26 | | |
NCT04399564: Temporary vs.Long Term Hemodialysis Catheter on Central Vein Stenosis |
|
|
| Not yet recruiting | N/A | 80 | NA | temporary hemodialysis catheters, long-term hemodialysis catheters | Shanghai Pudong Hospital | Stenosis of Arteriovenous Dialysis Fistula | 06/21 | 06/21 | | |
| Not yet recruiting | N/A | 230 | NA | active comarator using antiviral drug of nucleoside analogues, HA+purification | Shanghai Pudong Hospital | Chronic Hepatitis b | 09/23 | 09/23 | | |
| Li, Shu |
NCT05102149: Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 3 | 672 | RoW | PB-201, Vildagliptin, PB-201 matched placebo, Vildagliptin matched placebo | PegBio Co., Ltd. | Type 2 Diabetes Mellitus (T2DM) | 11/23 | 04/25 | | |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
| Completed | 3 | 257 | RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases | 07/24 | 07/24 | | |
NCT06633783: A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy® |
|
|
| Not yet recruiting | 3 | 370 | RoW | Semaglutide | Hangzhou Jiuyuan Gene Engineering Co. Ltd., | Obesity | 05/26 | 10/26 | | |
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone |
|
|
| Active, not recruiting | 3 | 520 | Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Type 2 Diabetes | 04/25 | 04/25 | | |
NCT05963022: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) |
|
|
| Completed | 3 | 168 | RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Type 2 Diabetes | 10/24 | 10/24 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
LEAD, NCT05092412: Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC |
|
|
| Active, not recruiting | 2 | 30 | RoW | Low-dose radiotherapy, Durvalumab, Etoposide, and cisplatin/carboplatin | You Lu, AstraZeneca | Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab | 02/23 | 06/25 | | |
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 2 | 318 | RoW | HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Type 2 Diabetes | 04/25 | 04/25 | | |
NCT06240104: Monitoring of Heart to Guide Myocardial Injury Patients to Wean From Ventilation |
|
|
| Recruiting | N/A | 200 | RoW | cardiac output index monitor | Peking University People's Hospital | Myocardial Ischaemia During Surgery | 12/25 | 12/25 | | |
NCT06386120: Respiratory Function Monitoring of Mechanical Ventilation in Patients With Chest Blunt Injury |
|
|
| Not yet recruiting | N/A | 80 | NA | PEEP setting strategy | Peking University People's Hospital | Lung Contusion | 05/26 | 07/26 | | |
NCT05230381: Intravenous Tranexamic Acid Reducing Intraoperative Blood Loss in Huge Meningiomas Resection |
|
|
| Recruiting | N/A | 228 | RoW | Continous infusion, Single infusion, Placebo | Beijing Tiantan Hospital | Tranexamic Acid, Intraoperative Blood Loss, Meningioma | 12/24 | 06/25 | | |
NCT06041659: Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia |
|
|
| Recruiting | N/A | 48 | RoW | | Beijing Tiantan Hospital | Moyamoya Disease | 12/25 | 12/25 | | |
| Zhang, Yaojun |
NCT06467799: Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC |
|
|
| Not yet recruiting | 2 | 39 | NA | Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 | Sun Yat-sen University | Hepatocellular Carcinoma, Beyond Milan Criteria | 07/25 | 07/26 | | |
NCT06524466: Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2 | 35 | RoW | Neoadjuvant SBRT combined with Lenvatinib and Pucotenlimab | Sun Yat-sen University | Resectable Hepatocellular Carcinoma, Macrovascular Invasion, CNLC IIIA Stage | 12/26 | 12/26 | | |
| Recruiting | 1 | 9 | RoW | BST02 | BioSyngen Pte Ltd | Locally Advanced Liver Carcinoma | 07/25 | 12/25 | | |
NCT04641468: Clinical Efficacy and Safety of a Prospective, Multicenter Drug Coated Balloon for Left Main Artery Disease in China |
|
|
| Recruiting | N/A | 30 | RoW | DCB, optical coherence tomography | Xuzhou Third People's Hospital | Coronary Diseases, Left Main Coronary Artery Disease, Bifurcation Lesions | 12/20 | 12/21 | | |
EXPECT, NCT04375319: OCT Evaluation of Early Vascular Repair in Patients With Non ST Elevation Acute Coronary Syndrome (NSTE-ACS) |
|
|
| Recruiting | N/A | 60 | RoW | OCT, optical coherence tomography | Xuzhou Third People's Hospital, Shandong Jiwei Medical Products Co., Ltd | Unstable Anginas, Non ST Segment Elevation Myocardial Infarction | 12/23 | 12/23 | | |
NCT06166459: Yao Strategy for the Treatment of de Novo Medina 0,1,0 or 0,0,1 Bifurcation Lesion |
|
|
| Not yet recruiting | N/A | 200 | NA | Drug-coated balloon combined with provisional drug-eluting stent implantation | Xuzhou Third People's Hospital | Coronary Artery Disease, Bifurcation Lesion | 03/26 | 03/26 | | |
| Not yet recruiting | N/A | 5000 | RoW | | Sun Yat-sen University | Liver Neoplasms | 12/39 | 12/44 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
